Previously, the company developed and tested a bovine form of AP in three phase II trials in patients with sepsis, AKI and UC.AM-Pharma has since developed and manufactured a proprietary and fully human recombinant form of AP, known as recAP.
Timeline
September 13, 2011
AM Pharma raises a $39,843,400 series D round from BB Biotech Ventures, Forbion Capital Partners, IDInvest Partners, Inventages Venture Capital Investment Inc., Kurma Life Science Partners, Shire and Ysios Capital.
Funding rounds
Patents
Products
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
References
Is a
CompanyCompany attributes
Industry
Microbiome
Biomedical engineeringLocation
Netherlands
Andera Partners
Kurma Partners
Kurma Life Science Partners
Shire (pharmaceutical company)
Forbion Capital PartnersTotal funding amount (USD)
172,843,400
Latest funding round date
July 2019
Latest funding type
Other attributes
Country
